Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19-Reference-Cited by-同舟云学术

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

Published:2021-04-09 Issue:3 Volume:14 Page:1133-1146
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Delaunois Annie¹,Abernathy Matthew²,Anderson Warren D.³,Beattie Kylie A.⁴,Chaudhary Khuram W.⁵,Coulot Julie⁶,Gryshkova Vitalina¹,Hebeisen Simon⁶,Holbrook Mark⁷,Kramer James⁸,Kuryshev Yuri⁸,Leishman Derek²,Lushbough Isabel¹,Passini Elisa⁹,Redfern Will S.⁷,Rodriguez Blanca⁹,Rossman Eric I.⁵,Trovato Cristian⁹,Wu Caiyun⁸,Valentin Jean‐Pierre¹

Affiliation:

1. UCB Biopharma SRL Braine‐l’Alleud Belgium

2. Eli Lilly and Company Lilly Corporate Center Indianapolis Indiana USA

3. Center for Public Health Genomics University of Virginia Charlottesville Virginia USA

4. GlaxoSmithKline Stevenage UK

5. GlaxoSmithKline Collegeville Pennsylvania USA

6. B’SYS GmbH Witterswil Switzerland

7. Certara UK Ltd Sheffield UK

8. Charles River Cleveland Ohio USA

9. Department of Computer Science University of Oxford Oxford UK

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13011

Reference46 articles.

1. Comprehensive in vitro proarrhythmia assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative;Cavero I;Expert Opin Drug Saf,2014

2. Evolution of strategies to improve preclinical cardiac safety testing

3. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm

4. Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study

5. Cardiotoxicity of antimalarial drugs

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials;Toxicological Sciences;2024-07-08

2. HPC Framework for Performing in Silico Trials Using a 3D Virtual Human Cardiac Population as Means to Assess Drug-Induced Arrhythmic Risk;Methods in Molecular Biology;2023-09-14

3. “Appraisal of state-of-the-art” The 2021 Distinguished Service Award of the Safety Pharmacology Society: Reflecting on the past to tackle challenges ahead;Journal of Pharmacological and Toxicological Methods;2023-09

4. Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA);Frontiers in Pharmacology;2023-08-15

5. Hydroxychloroquine and azithromycin alter the contractility of living porcine heart slices;Frontiers in Pharmacology;2023-05-05